Structure details positive trial data for a weight-loss pill, and the stock rockets
Up next
Author


Structure Therapeutics is developing a daily GLP-1 receptor pill called aleniglipron, that just showed positive results from a Phase 2 trial.

You May Also Like
Treasury yields hold steady with U.S. GDP revision due

Treasury yields hold steady with U.S. GDP revision due

Treasury yields were trading steady on Wednesday, as investors awaited fresh data…
Oracle’s stock is having its best day in more than 3 years. Why Wall Street is so upbeat.

Oracle’s stock is having its best day in more than 3 years. Why Wall Street is so upbeat.

Analysts say Oracle’s spending forecast and business commitments suggest more momentum ahead.
Biden says ‘working-class people are still in trouble.’ These 4 expenses are still pinching consumers, even as inflation cools.

Biden says ‘working-class people are still in trouble.’ These 4 expenses are still pinching consumers, even as inflation cools.

Donald Trump and Joe Biden sparred on inflation, and what caused it,…
Morgan Stanley expects Novo Nordisk Alzheimer trial to fail as it slashes rating

Morgan Stanley expects Novo Nordisk Alzheimer trial to fail as it slashes rating

Morgan Stanley analysts say a trial to test whether Novo Nordisk’s blockbuster…